Drug Database · Clinicians

Gliclazide + Metformin

Brands (6) Glyzeric, Clazimet, Glimetsaph…Show all

Oral hypoglycemic (biguanide-sulfonylurea combination); Oral hypoglycemic combination); and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug8 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: Type 2 diabetes, modified-release (MR) renalcarematters.com, reviewed

    Kidney dosing: Gliclazide (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Usual dosing. Modified-release (MR): 30 to 120 mg once daily at breakfast. Immediate-release 80 mg tablets: 40 to 80 mg/day to start, maximum 320 mg/day; doses above 160 mg/day are split before breakfast and dinner (SmPC).
    CrCl 30–59 mL/min
    Mild to moderate impairment: same regimen as normal kidney function with careful glucose monitoring (MR SmPC). Immediate-release: use caution above 160 mg/day and consider limiting the maximum dose as serum creatinine rises (IR SmPC). Start at the lowest dose (MR 30 mg or IR 40–80 mg) and titrate slowly; reduce if hypoglycemia occurs (KDIGO 2022, Figure 6).
    CrCl 15–29 mL/min
    Severe renal insufficiency: contraindicated; insulin is recommended (SmPC). Our mapping of 'severe' to CrCl <30 is a judgment. Off-label use below 30 is a specialist decision: lowest dose, close glucose monitoring.
    CrCl <15 mL/min (not on dialysis)
    Contraindicated (severe renal insufficiency; SmPC).
    Hemodialysis (intermittent)
    Contraindicated (severe renal insufficiency; SmPC). Dialysis does not remove gliclazide because it is highly protein-bound (SmPC 4.9).
    Peritoneal dialysis
    Contraindicated (severe renal insufficiency; SmPC).
    CRRT
    Not appropriate; contraindicated in severe renal insufficiency (SmPC). Use insulin.
    • Dialyzable? No: dialysis is of no benefit in overdose because gliclazide is about 95% protein-bound (SmPC 4.9).
    • Monitoring Glucose (fasting plasma glucose, glycated hemoglobin [HbA1c], self-monitoring). Hypoglycemia can be prolonged in severe kidney impairment and needs longer observation (SmPC 4.4). Reassess kidney function periodically. G6PD deficiency: sulfonylureas can cause hemolytic anemia; use with caution and consider a non-sulfonylurea alternative (SmPC 4.4).

    From the Gliclazide monograph (renalcarematters.com, reviewed).

  • Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label

    Kidney dosing: Metformin (single-agent)
    Show full dosing details
    eGFR ≥60
    Usual dosing. Assess kidney function before starting and periodically (label).
    eGFR 30–59
    eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
    eGFR 15–29
    Contraindicated (label). Stop if eGFR falls below 30.
    eGFR <15 (not on dialysis)
    Contraindicated (label).
    Hemodialysis (intermittent)
    Contraindicated (eGFR <30 per label).
    Peritoneal dialysis
    Contraindicated (eGFR <30 per label).
    CRRT
    Not appropriate; contraindicated in severe kidney impairment (label).
    • Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
    • Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).

    From the Metformin monograph (renalcarematters.com, reviewed).

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 80 mg/500 mg, 500 mg/80 mg, 850 mg/80 mg
  • Tablet: 80 mg/500 mg
  • Sustained-release tablet: 500 mg/30 mg

Registered products in the Philippines

8 products registered with the Food and Drug Administration (FDA) Philippines list Gliclazide + Metformin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products8
Philippine FDA-registered products for Gliclazide + Metformin
Package insert
ClazimetMetformin Hydrochloride + Gliclazide
500 mg/80 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.
DRP-18916
Sep 29, 2031
GlimetsaphGliclazide + Metformin Hydrochloride
80 mg/500 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-18509
Jul 27, 2031
GlyzericMetformin hydrochloride + Gliclazide
500 mg/80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY43023
Nov 27, 2028
GlyzericMetformin Hydrochloride + Gliclazide
500 mg/80 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48178
Jul 11, 2027
GlyzericMetformin hydrochloride + Gliclazide
850mg/80mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY43024
Nov 27, 2028
Melanov -MGliclazide + Metformin Hydrochloride
80 mg/500 mg tabletAlu/Alu Blister Pack by 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY43936
Dec 2, 2029
Melanov M ODMetformin hydrochloride + Gliclazide
500 mg/30 mg Sustained - Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY48329
Sep 6, 2027
SaphzimetGliclazide + Metformin Hydrochloride
80 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-13393
Feb 10, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .